Literature DB >> 35129637

Murine myeloid derived suppressor cells possess a range of suppressive mechanisms-Granzyme B is not among them.

Ellis Tibbs1, Xuefang Cao2,3.   

Abstract

This paper addresses the controversy of Granzyme B (GzmB) expression by murine Myeloid Derived Suppressor Cells (MDSCs). MDSCs are a heterogenous immature myeloid population that are generated in chronic inflammatory pathologies for the purpose to suppress inflammatory responses. MDSCs express a multitude of factors to induce suppressive function such as PD-L1, reactive oxygen species (ROS), nitric oxide synthase (iNOS), and Arginase-1. Recently, Dufait et al. sought to demonstrate GzmB as an additional mechanism for suppression by MDSCs. They reported that murine MDSCs not only significantly express GzmB as well as Perforin (Prf1), but this expression is functionally important for tumor growth in vivo as well as tumor migration in vitro. We conducted experiments to address the same question but made confounding observations: MDSCs under stringent developmental process do not express GzmB. Our results show that not only GzmB protein is not produced at functional level, but the mRNA transcript is not detectable either. In fact, the GzmB protein found in the media of MDSC culture was due to T cells or natural killer cells contained in bone marrow and cultured alongside MDSCs. We strengthen this finding by genetically deleting GzmB from the myeloid lineage and measuring tumor burden compared to WT counterpart. Our results show no significant difference in tumor burden, suggesting that even if there is minor expression of GzmB, it is not produced at a functional amount to affect tumor growth. Therefore, this paper proposes alternative theories that align with the known understanding of GzmB expression and secretion.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Granzyme B; Immune suppression; Myeloid derived suppressor cells

Mesh:

Substances:

Year:  2022        PMID: 35129637     DOI: 10.1007/s00262-022-03162-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  36 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

2.  TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes.

Authors:  Xiaoyu Xiang; Yuelong Liu; Xiaoyin Zhuang; Shuangqin Zhang; Sue Michalek; Douglas D Taylor; William Grizzle; Huang-Ge Zhang
Journal:  Am J Pathol       Date:  2010-08-27       Impact factor: 4.307

3.  Expression of granzyme B in peripheral blood polymorphonuclear neutrophils (PMN), myeloid cell lines and in PMN derived from haemotopoietic stem cells in vitro.

Authors:  Christof Wagner; Sabine Stegmaier; Gertrud Maria Hänsch
Journal:  Mol Immunol       Date:  2007-11-09       Impact factor: 4.407

4.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

5.  Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

Authors:  Fanny Chalmin; Sylvain Ladoire; Grégoire Mignot; Julie Vincent; Mélanie Bruchard; Jean-Paul Remy-Martin; Wilfrid Boireau; Alain Rouleau; Benoit Simon; David Lanneau; Aurélie De Thonel; Gabriele Multhoff; Arlette Hamman; François Martin; Bruno Chauffert; Eric Solary; Laurence Zitvogel; Carmen Garrido; Bernhard Ryffel; Christophe Borg; Lionel Apetoh; Cédric Rébé; François Ghiringhelli
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

6.  Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation.

Authors:  Zhen Bian; Ahmed Mansour Abdelaal; Lei Shi; Hongwei Liang; Lanqiao Xiong; Koby Kidder; Mahathi Venkataramani; Courtney Culpepper; Ke Zen; Yuan Liu
Journal:  Eur J Immunol       Date:  2018-03-23       Impact factor: 5.532

7.  Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells.

Authors:  Zuping Zhou; Deborah L French; Ge Ma; Samuel Eisenstein; Ying Chen; Celia M Divino; Gordon Keller; Shu-Hsia Chen; Ping-Ying Pan
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

8.  Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis.

Authors:  Won-Jung Kim; Ho Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Immunol Lett       Date:  2007-06-08       Impact factor: 3.685

9.  L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.

Authors:  Yu Cao; Yonghui Feng; Yanjun Zhang; Xiaotong Zhu; Feng Jin
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

10.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.

Authors:  Muhammad Zaeem Noman; Giacomo Desantis; Bassam Janji; Meriem Hasmim; Saoussen Karray; Philippe Dessen; Vincenzo Bronte; Salem Chouaib
Journal:  J Exp Med       Date:  2014-04-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.